September 25, 2020

The Niche

Knoepfler lab stem cell blog

ViaCyte

7 min read

It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on their clinical trial, the healthy competition with Doug Melton, and future perspectives. Can you give an update on the VC-01 clinical trial? Answer: We’ve enrolled four patients in the …Read More